MOLCURE Inc. and KM Biologics Co., Ltd. today announced that they have entered into a research agreement aimed at the discovery of innovative biopharmaceuticals in the field of hematology by leveraging MOLCURE’s proprietary AI-powered drug discovery platform.
Under this collaboration, MOLCURE’s advanced AI platform—which is built around its proprietary large language models (LLMs) — will be integrated with KM Biologics’ deep domain expertise in hematology. By actively incorporating KM Biologics’ extensive R&D insights and research outcomes into the AI learning process, the partnership seeks to unlock novel therapeutic approaches and accelerate the creation of breakthrough medicines.
“We are honored that KM Biologics has selected MOLCURE as their partner to drive innovation in drug discovery,” said Satoshi Tamaki, CEO and CSO of MOLCURE. “By synergizing KM Biologics’ specialized knowledge with our AI capabilities, we look forward to developing transformative treatments that improve clinical outcomes and enhance the quality of life for patients worldwide.”
About MOLCURE
MOLCURE Inc. is a leader in AI-driven drug discovery for antibodies and peptides. Our platform combines cutting-edge large language models (LLMs), physics-based simulations, and high-quality experimental data from our in-house labs. This approach enables the discovery of innovative biologics that are safer and more effective, making it possible to tackle undrugged targets that other technologies cannot reach. We work with forward-thinking partners, including leading pharmaceutical companies, to accelerate R&D and help bring life-changing new treatments for patients around the world. Founded in 2013, MOLCURE is based in Japan, with headquarters in Kawasaki and a research facility in Tsuruoka. Learn more at https://molcure.com.
About KM Biologics
KM Biologics Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sales of biological products, with a primary focus on vaccines and plasma-derived therapeutics. The company operates across four key business domains—human vaccines, animal vaccines, plasma derivatives, and newborn screening—and contributes to the advancement of public health under its mission of protecting people’s health and lives. KM Biologics is committed to ensuring a stable supply of essential and hard-to-replace medicines, including albumin preparations and blood coagulation factor products, thereby supporting the treatment of rare diseases. The company is also actively involved in strengthening rapid-response supply capabilities during infectious disease outbreaks, promoting infection prevention initiatives． Looking ahead, KM Biologics remains dedicated to delivering safer and more reliable products while continuing to play an important role in improving public health. For further information, please visit https://www.kmbiologics.com.
For media and business inquiries:
Tsunehiko Kohashi
MOLCURE Inc.
contact＠molcure.io
044-400-1894
